INTRODUCTION
============

Nasopharyngeal carcinoma (NPC) is a rare disease on a world scale, and it accounted for 0.7% of all cancers, and ranked the 23rd most common new cancer in the world.^[@B1]^ However, it is endemic in some specific areas, such as in Hong Kong, and south of China.^[@B1]^ The intermediate rates are observed in several indigenous populations in South East Asia and in natives of the Arctic region, North Africa and the Middle East.^[@B1]^ Epstein-Barr Virus (EBV) is a well known risk factor for NPC. Patients with NPC are noted to have high levels of EBV antibodies.^[@B2],[@B3]^ The infection of EBV is not associated directly in inducing by the tumor, but infection in the healthy individuals means increased risk of cancer.^[@B4]-[@B6]^

Several diagnostic methods are used for NPC detection, but the EBV serology examinations test IgA antibodies against viral capsid antigen (VCA) to IgA to early antigen are the most common detection methods for diagnosis of NPC.^[@B2]^ This method is cheap and non- invasive, and therefore, it is acceptable for patients and could be widely used in clinics. Quantitative EBV DNA and VCA-IgA analysis has been reported to be a sensitive detection tool in diagnosis of NPC.^[@B7],[@B8]^

Recent studies indicated the cell-free EBV DNA had high detection rate in the plasma and serum among patients with NPC.^[@B9],[@B10]^ Recently several studies have showed plasma EBV-DNA and VCA-IgA level might be a sensitive and reliable biomarker for the diagnosis of NPC at a molecular level in clinical practice.^[@B11]-[@B14]^ However, the there is no consensus yet which is a better test for the early diagnosis of nasopharyngeal carcinoma. Reasons may include the different sources of EBV antigens, different antibody assays and the selection of cases from different geographic origins. Therefore, we conducted a meta-analysis to evaluate which EBV serology examination had the better sensitivity and specificity in the diagnosis of NPC.

METHODOLOGY
===========

***Searching strategy:***Three databases, Medline (from Jan. 1966 to Jan. 2012), EMBASE (from January 1988 to Jan. 2012) and Chinese Biomedical Database (from January 1980 to Jan. 2012), were systematically searched by using related terms ('Epstein-Barr Virus', 'EBV', 'DNA', 'VCA-IgA', 'serological test', 'nasopharyngeal carcinoma' (NPC). There was no restriction on the language of the papers. References cited in retrieved studies were reviewed for more eligible studies. The criteria used for including studies were (1) Case-control or cohort studies on the role of EBV-DNA and VCA-IgA in diagnosis of NPC; (2) identification of NPC was confirmed histologically/pathologically; (3) Available data regarding sensitivity and specificity of EBV-DNA and VCA-IgA in diagnosis of NPC; If the authors reported more than once the data on publication papers, we only included the complete data into our review. The exclusion criteria were case only study, reviews, and overlapping studies.

***Data extraction:***Two reviewers independently reviewed the final abstracts of all potential articles, and decided one should be included into final meta-analysis. In case there was any disagreement, it was resolved by discussion. If the data were missing in the included studies, we attempted to contact the authors by emails or telephones in order to include complete data. From these finally selected studies, we included author's names, location, study type, number of participants of studies in terms of EBV-DNA and VCA-IgA ([Table-I](#T1){ref-type="table"}).

***Quality of study:***The quality of included studies was according to the Cochrane Handbook for diagnostic test accuracy review. The criteria included sampling, data collection, design of study, detection application and selection bias. The quality scores ranged from 0 to 10. Score\<6 was defined as low quality, and score≥6 was defined as high quality.

***Statistical analysis:***Statistical analysis was conducted by using Meta-DiSc statistical software version 1.4 (Unit of Clinical Biostatistics, Ramony Cajal Hospital, Madrid, Spain). The accuracy indexes of EBV-DNA and VCA-IgA was pooled by meta-analysis, such as sensitivity, specificity, positive likelihood ratio (LR+) and negative likelihood ratio (LR--). The heterogeneity was evaluated by I^2^ with p-values \< 0.1. The I^2^ value of 25%, 50% and 75% were regarded as low, moderate and high heterogeneity, respectively (Higgins et al., 2003)^[@B39]^ and its possible sources of heterogeneity were evaluated by subgroup analysis. If moderate or high heterogeneity existed, the random effects model was used. Otherwise, a fixed-effect model was used for pooled results. Summary receiver operating characteristic (SROC) curve was used for evaluating the global summary of test performance, and the area under the SROC curve presents the overall performance of the detection method. The area under the curve of 1 presents perfect discriminatory ability. All P values are two sides and P\<0.05 was regarded as statistical significant.

RESULTS
=======

***Characteristics of studies:*** A total of 758 records were selected by searching the databases. After excluding the overlapping studies and those which were not in line with the inclusion criteria. A total of 29 studies were included and assessed for meta-analysis. After reviewing the original paper, we excluded 2 studies. Finally, 27 case-control and cohort studies were included in final analysis. A total of 2717 cases and 4085 controls were included in our meta-analysis ([Table-I](#T1){ref-type="table"}).

###### 

Characteristics of included studies

  *Study ID*               *Location*       *Sample size*   *Method*   *Study design*        *Score of bias*   
  ------------------------ ---------------- --------------- ---------- --------------------- ----------------- ---
  Zhang 2012\[15\]         Mainland China   40              50         EBA DNA               Case-control      6
  Zhu 2012\[16\]           Mainland China   168             60         EBA DNA and VCA-IgA   Case-control      6
  Feng 2009 \[17\]         Mainland China   65              29         EBA DNA and VCA-IgA   Case-control      7
  Kong 2010 \[18\]         Mainland China   56              60         EBA DNA               Case-control      9
  Liao 2010 \[19\]         Mainland China   34              30         EBA DNA and VCA-IgA   Case-control      4
  Sun 2010 \[20\]          Mainland China   62              62         EBA DNA and VCA-IgA   Case-control      5
  Tan 2010\[21\]           Mainland China   12              40         EBA DNA and VCA-IgA   Case-control      3
  Wai 2010\[22\]           Hong Kong        18              1181       EBA DNA               Case-control      8
  Luo 2009 \[23\]          Mainland China   160             76         EBA DNA and VCA-IgA   Case-control      5
  Chang 2008 \[24\]        Mainland China   156             265        EBA DNA               Cohort            5
  Sun 2008\[25\]           Mainland China   68              90         EBA DNA and VCA-IgA   Case-control      5
  Ozyar 2007\[26\]         Turkey           24              29         EBA DNA               Case-control      7
  O 2007\[27\]             United State     24              84         EBA DNA and VCA-IgA   Case-control      8
  Li 2007\[28\]            China            781             171        VCA-IgA               Case-control      5
  Huang 2006\[29\]         China            184             80         VCA-IgA               Case-control      5
  Leung 2004 \[30\]        Hong Kong        139             178        EBA DNA and VCA-IgA   Case-control      7
  Shao 2004\[31\]          Mainland China   147             78         EBA DNA               Case-control      6
  Fan 2004\[32\]           Mainland China   65              68         EBA DNA and VCA-IgA   Case-control      5
  Krishna 2004\[33\]       India            17              15         EBA DNA               Case-control      6
  Chan 2003\[34\]          Mainland China   55              163        EBA DNA and VCA-IgA   Case-control      5
  Pratesi 2003\[35\]       Italy            15              32         EBA DNA               Case-control      7
  Fang 2003\[36\]          China            114             842        VCA-IgA               Case-control      5
  Huang 2003\[37\]         China            84              60         VCA-IgA               Case-control      4
  Mai 2002\[38\]           Mainland China   66              58         EBA DNA               Case-control      5
  Mutirangura 1998\[8\]    Thailand         13              111        EBA DNA               Case-control      7
  Shotelersuk 2000\[39\]   Thailand         93              130        EBA DNA               Case-control      6
  Lo 1999\[9\]             Hong Kong        57              43         EBA DNA               Case-control      8
  Total                                     1554            2932                                               

###### 

The diagnostic characteristics of included studies in terms of EBV-DNA

  *Study ID*         *TP*   *FP*   *FN*   *TN*   *Sensitivity(95% CI)*   *Specificity(95% CI)*   *+LR(95% CI)*         *-LR(95% CI)*
  ------------------ ------ ------ ------ ------ ----------------------- ----------------------- --------------------- ------------------
  Zhang 2012         27     10     13     40     0.68(0.51-0.81)         0.80(0.66-0.90)         3.38(1.86-6.12)       0.41(0.26-0.65)
  Zhu 2012           58     2      110    58     0.35(0.27-0.42)         0.97(0.88-1.0)          10.36(2.61-41.1)      0.68(0.60-0.76)
  Kong 2010          41     7      15     53     0.73(0.60-0.84)         0.88(0.77-0.95)         6.28(2.07-12.82)      0.30(0.20-0.47)
  Liao 2010          20     3      14     27     0.59(0.41-0.75)         0.90(0.74-0.98)         5.88(1.94-17.85)      0.46(0.30-0.70)
  Sun 2010           59     4      3      58     0.94(0.86-0.99)         0.94(0.84-0.98)         14.75(5.71-38.12)     0.05(0.02-0.16)
  Tan 2010           33     0      90     40     0.27(0.91-1.0)          1.00(0.91-1.0)          22.15(1.39-353.54)    0.74(0.66-0.83)
  Wai 2010           15     153    3      1028   0.83(0.57-0.96)         0.87(0.85-0.89)         6.43(4.99-8.29)       0.19(0.07-0.54)
  Feng 2009          45     1      20     28     0.69(0.57-0.80)         0.97(0.82-0.99)         20.08(2.91-138.69)    0.32(0.22-0.46)
  Luo 2009           110    9      50     67     0.69(0.61-0.76)         0.88(0.79-0.94)         5.81(3.12-10.82)      0.35(0.28-0.45)
  Chang 2008         127    9      29     255    0.81(0.74-0.87)         0.97(0.94-0.98)         23.88(12.51-45.58)    0.19(0.14-0.27)
  Sun 2008           65     6      3      84     0.96(0.88-0.99)         0.93(0.86-0.98)         14.34(6.61-31.11)     0.05(0.02-0.14)
  Ozyar 2007         24     10     0      19     1.00(0.86-1.00)         0.66(0.46-0.82)         2.8(1.71-4.57)        0.03(0.01-0.48)
  O 2007             17     7      5      79     0.77(0.55-0.92)         0.92(0.84-0.97)         9.49(4.51-20.0)       0.25(0.11-0.54)
  Leung 2004         132    4      7      174    0.95(0.90-0.98)         0.98(0.94-0.99)         42.26(16.02-111.44)   0.05(0.03-0.11)
  Fan 2004           64     29     1      39     0.99(0.92-1.0)          0.57(0.45-0.69)         2.31(1.75-3.05)       0.03(0.01-0.19)
  Shao 2004          138    12     9      66     0.94(0.88-0.97)         0.85(0.75-0.92)         6.10(3.62-10.29)      0.07(0.04-0.14)
  Krishna 2004       15     2      5      10     0.75(0.51-0.91)         0.83(0.52-0.98)         4.5(1.24-16.35)       0.3(0.14-0.67)
  Chan 2003          31     3      24     160    0.56(0.42-0.70)         0.98(0.95-0.99)         30.62(9.75-96.23)     0.45(0.33-0.60)
  Pratesi 2003       15     20     0      12     1.0(0.78-1.0)           0.38(0.21-0.56)         1.56(1.18-2.07)       0.08(0.01-1.31)
  Mai 2002           56     6      10     52     0.85(0.74-0.93)         0.90(0.79-0.96)         8.20(3.82-17.62)      0.17(0.10-0.30)
  Mutirangura 1998   13     29     0      82     1.0(0.75-0.82)          0.74(0.65-0.82)         3.66(2.64-5.07)       0.05(0.003-0.74)
  Shotelersuk 2000   83     63     10     67     0.89(0.81-0.94)         0.52(0.43-0.60)         1.84(1.52-2.23)       0.21(0.11-0.38)
  Lo 1999            55     3      2      40     0.97(0.88-0.95)         0.93(0.81-0.99)         13.83(4.64-41.24)     0.04(0.01-0.15)
  Pooled results     1243   392    423    2538   0.75(0.72-0.76)         0.87(0.85-0.88)         6.98(4.50-10.83)      0.18(0.11-0.29)

###### 

The diagnostic characteristics of included studies in terms of VCA-IgA

  *Study ID*       *TP*   *FP*   *FN*   *TN*   *Sensitivity*     *Specificity*     *+LR(95% CI)*          *-LR(95% CI)*
  ---------------- ------ ------ ------ ------ ----------------- ----------------- ---------------------- -----------------
  Zhu 2012         105    2      53     28     0.67(0.58-0.74)   0.93(0.78-0.99)   9.97(2.60-38.20)       0.36(0.28-0.46)
  Liao 2010        15     1      19     29     0.44(0.27-0.61)   0.97(0.83-0.99)   13.24(1.86-94.32)      0.58(0.43-0.79)
  Sun 2010         58     32     5      58     0.92(0.82-0.97)   0.64(0.54-0.74)   2.59(1.94-3.45)        0.12(0.05-0.29)
  Tan 2010         88     1      35     39     0.72(0.63-0.79)   0.98(0.87-1.0)    28.62(4.12-198.85)     0.29(0.22-0.39)
  Luo 2009         120    4      40     72     0.75(0.68-0.82)   0.95(0.87-0.89)   14.25(5.47-37.14)      0.26(0.20-0.35)
  Sun 2008         15     153    3      1028   0.83(0.59-0.96)   0.87(0.85-0.89)   6.43(4.99-8.29)        0.19(0.07-0.54)
  O 2007           29     57     3      66     0.91(0.75-0.98)   0.54(0.44-0.63)   1.96(1.57-2.44)        0.18(0.06-0.52)
  Li 2007          704    0      77     171    0.90(0.88-0.92)   1.0(0.98-1.0)     309.91(19.46-4935.2)   0.10(0.08-0.12)
  Huang 2006       146    2      38     78     0.79(0.73-0.85)   0.98(0.91-0.99)   31.74(8.06-125.96)     0.21(0.16-0.28)
  Leung 2004       112    8      27     170    0.81(0.73-0.87)   0.96(0.91-0.98)   17.93(9.06-35.46)      0.20(0.15-0.29)
  Chan 2003        40     5      4      94     0.91(0.78-0.76)   0.95(0.89-0.98)   18.0(7.62-42.50)       0.10(0.04-0.24)
  Fang 2003        107    193    7      649    0.94(0.88-0.96)   0.77(0.74-0.80)   4.10(3.59-4.68)        0.08(0.04-0.16)
  Huang 2003       146    2      38     78     0.79(0.73-0.85)   0.98(0.91-1.0)    31.74(8.06-124.96)     0.21(0.16-0.28)
  Pooled results   1685   460    349    2560   0.83(0.81-0.85)   0.85(0.83-0.86)   10.89(5.41-21.93)      0.20(0.14-0.29)

###### 

The diagnostic characteristics of EBV DNA in plasma and serum

  *Subgroup*                    *TP*   *FP*   *FN*   *TN*   *Pooled Sensitivity*   *Pooled Specificity*   *Pooled +LR(95% CI)*   *Pooled -LR(95% CI)*   *SROC*
  ----------------------------- ------ ------ ------ ------ ---------------------- ---------------------- ---------------------- ---------------------- --------
  *High quality of studies*                                                                                                                             
  EBV-DNA                       678    323    199    1756   0.77(0.74-0.80)        0.85(0.83-0.86)        5.54(2.25-9.16)        0.16(0.07-0.37)        0.93
  VCA-IgA                       246    67     83     264    0.75(0.69-0.79)        0.80(0.75-0.84)        6.94(0.43-111.52)      0.25(0.13-0.47)        0.89
  *Low qu* *ality of studies*                                                                                                                           
  EBV-DNA                       565    69     224    782    0.72(0.68-0.75)        0.92(0.90-0.94)        10.20(4.27-24.36)      0.20(0.09-0.43)        0.96
  VCA-IgA                       1439   393    266    2296   0.84(0.82-0.86)        0.85(0.84-0.87)        13.05(5.69-29.93)      0.19(0.12-0.29)        0.944
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We analyzed the pooled sensitivity, specificity, positive likelihood (+LR) and likelihood negative (-LR) of EBV-DNA and VCA-IgA ([Table II](#T2){ref-type="table"} and [III](#T3){ref-type="table"}). The Sensitivity specificity, positive likelihood (+LR) and likelihood negative (-LR) of EBV-DNA in diagnosis of NPC were 0.75(0.72-0.76), 0.87(0.85-0.88), 6.98(4.50-10.83) and 0.18(0.11-0.29), respectively, and they were 0.83(0.81-0.85), 0.85(0.83-0.86), 10.89(5.41-21.93) and 0.20(0.14-0.29) for VCA-IgA.

The largest area of diagnosis under the summary receiver operator curve (AUC) for NPC by overall EBV DNA detection was 0.939, while the SROC was 0.936 for VCA-IgA detection ([Fig. 1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}). In the pooled analysis for EBV-DNA, there was significant heterogeneity across studies (p\<0.05, I^2^\>50%). While, no significant heterogeneity was found between studies in terms of VCA-IgA.

Subgroup analysis was taken according to the quality of studies to investigate the heterogeneity within the included studies ([Table-IV](#T4){ref-type="table"}), which indicated studies with low quality had lower sensitivity, specificity, +LR and -LR for both EBV-DNA and VCA-IgA detection. We could find the EBV-DNA had larger areas under the summary receiver operator curve when compared with VCA-IgA in high quality and low quality studies. The subgroup analysis significantly decreases the heterogeneity among studies, with the p value of 0.12 for EBV-DNA and 0.31 for VCA-IgA methods.

A single study in our meta-analysis was removed each time to analyze the robust of the pooled results, and the results did not greatly changed (Data not shown). The Egger's test were used to assess the publication bias, and no significant publication bias was found in our meta-analysis.

DISCUSSION
==========

Meta-analysis has been regarded as an important tool to more precisely define the effect of treatment for diseases and to identify potentially important sources of between-study heterogeneity. There is no systematic review to compare the EBV DNA and VCA-IgA in diagnosis of NPC. Only one previous study showed the sensitivity and specificity of EBV DNA in diagnosis of NPC^[@B38]^, but it could not reach a conclusive result whether EBV DNA is better for VCA-IgA. Hence, our study included 27 recently published studies comparing the effectiveness EBV DNA and VCA-IgA in diagnosis of NPC. Our meta-analysis involved 2757 cases and 4085 controls. Finally, we found EBV DNA had a higher accuracy than VCA-IgA in diagnosis of NPC. The EBV DNA had large SROC of 0.94, while the VCA-IgA had SROC of 0.936. Morever, the high quality of studies in terms of EBV DNA detection had high accuracy in diagnosis of NPC when compared with VCA-IgA (AUC of EBV DNA: 0.93; AUC of VCA-IgA: 0.89).

Heterogeneity is a potential problem in explaining the results of meta-analysis, and identifying the sources of heterogeneity is an important goals of meta-analysis.^[@B39]^ In our study, we assessed the between-study heterogeneity by using the I2 statistic to quantify the between-study heterogeneity^[@B39]^, and the results suggested great heterogeneity between studies in terms of EBV-DNA. Therefore, we further performed subgroup analysis by risk of bias. The results showed that risk of bias was an main source of heterogeneity.

There are two possible limitations in our meta-analysis which mainly influence the explanation of the results. Firstly, there might be publication bias in our study. All the studies included into meta-analysis were published paper; however, there might be many unfavorable results which may not have been published. We plan to include more studies in clinical trials registration and paper presented in conferences. Secondly, there might be selection bias in our study. Secondly as most of the studies included the NPC cases and controls in the same hospital or places, which could influence the results of study.

In conclusion, our results demonstrated the EBV DNA and VCA-IgA detection methods had better effect in diagnosis of NPC. However, EBV DNA detection method had high accuracy in diagnosis of NPC.
